JP2019510739A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019510739A5 JP2019510739A5 JP2018540415A JP2018540415A JP2019510739A5 JP 2019510739 A5 JP2019510739 A5 JP 2019510739A5 JP 2018540415 A JP2018540415 A JP 2018540415A JP 2018540415 A JP2018540415 A JP 2018540415A JP 2019510739 A5 JP2019510739 A5 JP 2019510739A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- composition according
- mammal
- gfral
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2016/074809 WO2017147742A1 (en) | 2016-02-29 | 2016-02-29 | Gfral receptor therapies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019510739A JP2019510739A (ja) | 2019-04-18 |
| JP2019510739A5 true JP2019510739A5 (enExample) | 2019-05-30 |
Family
ID=59742416
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018540415A Pending JP2019510739A (ja) | 2016-02-29 | 2016-02-29 | Ｇｆｒａｌ受容体療法 |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP3423094A4 (enExample) |
| JP (1) | JP2019510739A (enExample) |
| CN (1) | CN108697795A (enExample) |
| WO (1) | WO2017147742A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5977814B2 (ja) | 2011-04-08 | 2016-08-24 | アムジエン・インコーポレーテツド | 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を治療または改善する方法 |
| US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
| AU2017228489A1 (en) * | 2016-03-04 | 2018-09-06 | Ngm Biopharmaceuticals, Inc. | Compositions and methods for modulating body weight |
| WO2017172260A1 (en) | 2016-03-31 | 2017-10-05 | Ngm Bioparmaceuticals, Inc. | Binding proteins and methods of use thereof |
| MA46523A (fr) * | 2016-10-12 | 2019-08-21 | Janssen Biotech Inc | Procédés de criblage de modulateurs d'une activité biologique de type gdf15 |
| TWI724392B (zh) | 2018-04-06 | 2021-04-11 | 美商美國禮來大藥廠 | 生長分化因子15促效劑化合物及其使用方法 |
| AU2019368816B2 (en) | 2018-10-22 | 2025-01-30 | Janssen Pharmaceutica Nv | Glucagon like peptide 1 (GLP1)-growth differentiation factor 15 (GDF15) fusion proteins and uses thereof |
| WO2021067655A1 (en) | 2019-10-04 | 2021-04-08 | Amgen Inc. | Use of gdf15 for treating cardiometabolic syndrome and other conditions |
| BR112022006546A2 (pt) | 2019-10-07 | 2022-08-30 | Kallyope Inc | Agonistas de gpr119 |
| CA3173731A1 (en) | 2020-02-28 | 2021-09-02 | Kallyope, Inc. | Gpr40 agonists |
| CN116323608A (zh) | 2020-05-19 | 2023-06-23 | 卡尔优普公司 | Ampk活化剂 |
| WO2021246773A1 (ko) * | 2020-06-04 | 2021-12-09 | 재단법인대구경북과학기술원 | Gfral 길항 항체 및 이의 용도 |
| EP4172162A4 (en) | 2020-06-26 | 2024-08-07 | Kallyope, Inc. | AMPK ACTIVATORS |
| EP4314071A1 (en) | 2021-03-31 | 2024-02-07 | Cambridge Enterprise Limited | Therapeutic inhibitors of gdf15 signalling |
| AU2022303422B2 (en) * | 2021-06-30 | 2026-05-07 | Shanghai Jmt-Bio Technology Co., Ltd. | Anti-gfral antibody and application thereof |
| CN118580334A (zh) * | 2023-03-03 | 2024-09-03 | 北京志道生物科技有限公司 | 一种多肽分子 |
| IT202300006387A1 (it) * | 2023-03-31 | 2024-10-01 | Univ Degli Studi Roma La Sapienza | Inibitore del recettore gfral per uso nel trattamento della sclerosi laterale amiotrofica |
| CN116444667B (zh) * | 2023-06-13 | 2023-09-01 | 上海驯鹿生物技术有限公司 | 一种靶向gdf15的全人源抗体及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003213166B2 (en) * | 2002-03-05 | 2008-07-03 | Genentech, Inc. | Novel polypeptides having sequence similarity to GDNFR and nucleic acids encoding the same |
| EP2783698A1 (en) * | 2007-08-16 | 2014-10-01 | St Vincent's Hospital Sydney Limited | Agents and methods for modulating macrophage inhibitory cytokine (MIC-1) activity |
| JP5977814B2 (ja) * | 2011-04-08 | 2016-08-24 | アムジエン・インコーポレーテツド | 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を治療または改善する方法 |
| CN102321173B (zh) * | 2011-08-12 | 2013-04-03 | 中国医学科学院肿瘤研究所 | 人源化巨噬细胞抑制因子1单克隆抗体及其应用 |
| JO3462B1 (ar) * | 2012-08-22 | 2020-07-05 | Regeneron Pharma | أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها |
| CA2896076C (en) * | 2012-12-21 | 2022-12-06 | Aveo Pharmaceuticals, Inc. | Anti-gdf15 antibodies |
| WO2017121865A1 (en) * | 2016-01-15 | 2017-07-20 | Novo Nordisk A/S | Mic-1 receptor and uses thereof |
-
2016
- 2016-02-29 JP JP2018540415A patent/JP2019510739A/ja active Pending
- 2016-02-29 WO PCT/CN2016/074809 patent/WO2017147742A1/en not_active Ceased
- 2016-02-29 EP EP16891935.5A patent/EP3423094A4/en not_active Withdrawn
- 2016-02-29 CN CN201680082844.2A patent/CN108697795A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020536109A5 (enExample) | ||
| JP2012525128A5 (enExample) | ||
| JP2016512213A5 (enExample) | ||
| PE20220938A1 (es) | Compuestos agonistas de gipr | |
| JP2019506841A5 (enExample) | ||
| JP2020513809A5 (enExample) | ||
| JP2022513420A5 (enExample) | ||
| JP2018515088A5 (enExample) | ||
| RU2015127780A (ru) | Агонисты рецепторов глюкагона/glp-1 для лечения ожирения | |
| JP2016527286A5 (enExample) | ||
| JP2016539096A5 (enExample) | ||
| JP2012500006A5 (enExample) | ||
| JP2016534052A5 (enExample) | ||
| JP2014221758A5 (enExample) | ||
| JP2017510567A5 (enExample) | ||
| WO2016191643A4 (en) | Tigit-binding agents and uses thereof | |
| JP2018535948A5 (enExample) | ||
| JP2017500018A5 (enExample) | ||
| JP2016537340A5 (enExample) | ||
| JP2016020389A5 (enExample) | ||
| JP2023065390A (ja) | 治療用抗ｃｄ４０リガンド抗体 | |
| FI3569620T3 (fi) | Ihmisen cgrp-reseptoria sitovat vasta-aineet | |
| JP2016519650A5 (enExample) | ||
| JP2015522252A5 (enExample) | ||
| ES3001197T3 (es) | Agente de unión anti-adrenomedulina (ADM) para su uso en la terapia o prevención de síntomas de enfermedad |